Navigation Links
Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative Stress
Date:1/6/2014

rtable analyzer and disposable sensors that rapidly measure the level of oxidative stress and antioxidant reserves in biologic specimens via assessment of oxidation-reduction potential (ORP). ORP has been shown to be an important measure in both critical and chronic illnesses and is a novel marker of patient morbidity across a wide range of conditions. There are numerous clinical indications for this homeostatic parameter for which there is no currently available test. Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Contact:
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
2. Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
3. Quantum Materials Establishes Milestone as First Company to Deliver Tetrapod Quantum Dot Samples to LCD Display Manufacturer
4. Texas Childrens Hospital establishes the Jeffrey Modell Diagnostic & Research Center with a donation from the Jeffrey Modell Foundation
5. PA Governor Corbett: Americure Rx Establishes Operations in Lehigh Valley; Creates 51 Jobs
6. Winterhawk Consulting Establishes Partnership with Onapsis Inc to expand their SAP security offerings using Onapsis X1.
7. ICV Partners Establishes Dialysis Treatment Platform With Acquisition Of Atlantis Healthcare Group Puerto Rico, Inc.
8. Life Technologies Establishes International Influenza Network
9. H. D. Smith Establishes Specialty Solutions Organization And Realigns Senior Leadership To Support Growing Geographic Reach, Diversified Businesses
10. PQ Bypass Graduates from the Fogarty Institute for Innovation, Establishes Independent Operations
11. HYCOR Establishes Center Of Operations In Kassel, Germany To Provide Dedicated Support To European Distributors And Customers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014   OTEMR, Inc. , ONETOUCH EMR, ... certification, which designates that the software is capable of ... Stage 2 Meaningful Use measures required to qualify for ...  ONETOUCH EMR 2.0 was certified on July 14, 2014 ... National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant in ...
(Date:9/17/2014)... 2014  Members of the physician IT team ... announced today that the enterprise is working with ... sharing capabilities and provide immediate cluster fail over ... addition, the Dicom Systems enterprise imaging solutions will ... to more effectively deliver the right images to ...
(Date:9/17/2014)... 2014 Women everywhere know how frustrating a ... uncomfortable, they,re often also embarrassing and have a way ... Support ( http://ph-defense.com ) is a new, over-the-counter product ... homeopathic product. Odor, discharge, and discomfort ... infection. In many cases, the cause of such problems ...
Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3New Product from Vireo Systems: pH-D Feminine Health Support 2
... 2012  Ambit Biosciences and Teva Pharmaceutical Industries Limited (NASDAQ: ... of an Investigational New Drug application (IND)  with the U.S. ... (V600E) kinase inhibitor.  The IND filing ... as evidenced by data revealed in recent publications in ...
... - Atu027, a First in Class RNAi Therapy, Demonstrates Potential ... Biomarker Identified Silence Therapeutics to Announce New Data ... 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: ... (RNAi) therapeutics company, today announces that top line data from ...
Cached Medicine Technology:Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 2Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 3Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 4Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 5New Data from Silence's Atu027 Anticancer Trial Published at ASCO 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 3New Data from Silence's Atu027 Anticancer Trial Published at ASCO 4New Data from Silence's Atu027 Anticancer Trial Published at ASCO 5
(Date:9/17/2014)... PROVIDENCE, R.I. [Brown University] As Congress adjourns this ... bills senators will step over on their way out ... (SGR) Repeal and Medicare Provider Payment Modernization Act of ... JAMA Surgery , Dr. Eli Adashi recounts what he ... originally bipartisan bill. The perennial trouble with how Medicare ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Boston, MA (PRWEB) September 17, 2014 ... have partnered to create a monthly concert series, ... arts organization From the Top, America’s premier national ... classically-trained young musicians. Many of the young musicians ... the Top. , “Boston Children’s Museum is fortunate ...
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 Smart ... Editor’s Picks by Progressive Grocer, a leading trade magazine ... was awarded for originality and flavor, among other attributes. ... as an Editor’s Pick in the September print issue ... Grocer website. , The pizza won based on its ...
(Date:9/17/2014)... 17, 2014 StartX , a ... companies raising rounds of funding at its Summer Demo ... investors and media, was the first such gathering held ... to the university. The presentations were delivered on an ... StartX-QB3 Labs, a 2,000 square foot life science facility ...
Breaking Medicine News(10 mins):Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6
... to present findings at AMCP Conference in AprilST. ... Prime Therapeutics (Prime) revealed a significant reduction in ... a retrospective drug utilization review (RetroDUR) program paired ... research was recently published in the American Journal ...
... healing time and pain reduction, , , TUESDAY, April 14 ... production of stem cells appears to "jump-start" the bone-healing ... as fast as young people,s, suggest preliminary results released ... University of Rochester Medical Center in New York gave ...
... Expects to qualify for 180 days of sole marketing ... MYL ) today confirmed that the company and its ... Roche Inc. in connection with the filing of an ... and Drug Administration (FDA) for Capecitabine Tablets, 150 mg ...
... Pearl of Wisdom to Help Prevent Cervical Cancer UPPER MARLBORO, Md., ... knows about and benefits from the tools - the Pap test, ... from this disease. That,s the message that the Pearl of Wisdom(TM) ... women to get - and share - in honor of Mother,s ...
... Versus 2008 First Quarter; , EPS was $1.26, Equal to ... Johnson (NYSE: JNJ ) today announced sales of ... of 7.2% as compared to the first quarter of 2008. ... was 6.0%. Domestic sales declined 5.0%, while international sales declined ...
... The American Federation for Medical Research (AFMR) today has ... sectors to take action against the crisis in U.S. ... major U.S. government agencies, corporations and leading academic institutions ... clinical research from advancing in America. This lack of ...
Cached Medicine News:Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 2Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 3Health News:Slow-Healing Bones May Get Boost From Drug 2Health News:Slow-Healing Bones May Get Boost From Drug 3Health News:Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment 2Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 2Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 3Health News:Women's Health Advocates To Moms: We Can Beat Cervical Cancer! 4Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 2Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 3Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 4Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 5Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 6Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 7Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 8Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 9Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 10Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 11Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 12Health News:Johnson & Johnson Reports 2009 First-Quarter Results: 13Health News:The American Federation for Medical Research Unites Top Leaders to Mitigate U.S. Crisis in Clinical Research 2
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Standard Trephine...
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Long Handled Trephine...
Medicine Products: